Premium
Immunogenetics features and genomic lesions in splenic marginal zone lymphoma
Author(s) -
Rinaldi Andrea,
Forconi Francesco,
Arcaini Luca,
Mian Michael,
Sozzi Elena,
Zibellini Silvia,
Baldini Luca,
Franceschetti Silvia,
Gaidano Gianluca,
Marasca Roberto,
Mollejo Manuela,
Piris Miguel A.,
Tucci Alessandra,
Facchetti Fabio,
Bhagat Govind,
Favera Riccardo D.,
Rancoita Paola M. V.,
Zucca Emanuele,
Kwee Ivo,
Bertoni Francesco
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08347.x
Subject(s) - ighv@ , biology , splenic marginal zone lymphoma , lymphoma , genetics , immunology , pathology , antibody , medicine , chronic lymphocytic leukemia , leukemia , b cell
Summary Splenic marginal zone lymphomas (MZL) express mutated (M−) or unmutated (U−) immunoglobulin heavy chain (IGHV) genes. To investigate the IGHV mutational status impact on genetic lesions, this study combined single nucleotide polymorphism‐arrays and IGHV sequencing in 83 cases. Clinical features and outcome were similar between U‐ and M‐ IGHV cases. Recurrent lesions frequency was higher in U‐ IGHV cases, including poor prognosticators. Frequencies differed among cases bearing individual IGHV genes or lambda light chains. In conclusion, SMZL comprises subgroups based on genetic abnormalities and immunogenetic status. Genomic lesion frequency differed and was higher in U‐IGHV cases, possibly affecting the outcome.